March 14, 2025

Genomic Study Reveals Similarities, Differences in Ovarian Cancer Mutations Among Black, White Patients

Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian...

The ASCO Post

March 14, 2025

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug.

The ASCO Post

March 14, 2025

Cervical Precancer Incidence Decreases as HPV Vaccination Rates Rise

Recent findings from HPV-IMPACT project revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women.

The ASCO Post

March 14, 2025

Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

The ASCO Post

March 14, 2025

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual ...

The ASCO Post

March 13, 2025

Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC

Although the FDA-approved drugs sotorasib and adagrasib have provided hope to some patients with non-small cell lung cancer (NSCLC) by targeting KRAS G12C, the majority of tumors either resist treatme...

The ASCO Post

March 13, 2025

Association of Pathogenic Variants With Cancer Mortality

Oncologists often encounter patients who have pathogenic variants in certain genes known to increase the risk of breast, pancreatic, and colorectal cancers. But do these same variants increase mortali...

The ASCO Post

March 13, 2025

Impact of Duration of Neoadjuvant Immunotherapy in MMRd Colorectal Cancer

Does duration of neoadjuvant immunotherapy change the likelihood of pathologic complete response in patients with localized mismatch repair–deficient (MMRd) colorectal cancer?

The ASCO Post

March 13, 2025

Nivolumab Plus Cabozantinib Continues to Show Superior Long-Term Outcomes in Advanced Renal Cell Carcinoma

The PD-1 inhibitor nivolumab plus the tyrosine kinase inhibitor cabozantinib continues to demonstrate a significant survival advantage over sunitinib alone in patients with previously untreated advanc...

The ASCO Post